378 related articles for article (PubMed ID: 15329918)
1. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.
Breslow NE; Ou SS; Beckwith JB; Haase GM; Kalapurakal JA; Ritchey ML; Shamberger RC; Thomas PR; D'Angio GJ; Green DM
Cancer; 2004 Sep; 101(5):1072-80. PubMed ID: 15329918
[TBL] [Abstract][Full Text] [Related]
2. Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Green DM; Breslow NE; Evans I; Moksness J; D'Angio GJ
Med Pediatr Oncol; 1996 Mar; 26(3):147-52. PubMed ID: 8544795
[TBL] [Abstract][Full Text] [Related]
3. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
[TBL] [Abstract][Full Text] [Related]
5. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S; Haase G; Ritchey M; Kelalis P; D'Angio GJ
J Clin Oncol; 1998 Dec; 16(12):3744-51. PubMed ID: 9850017
[TBL] [Abstract][Full Text] [Related]
6. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study.
Pritchard J; Imeson J; Barnes J; Cotterill S; Gough D; Marsden HB; Morris-Jones P; Pearson D
J Clin Oncol; 1995 Jan; 13(1):124-33. PubMed ID: 7799012
[TBL] [Abstract][Full Text] [Related]
7. Effect of duration of treatment on treatment outcome for patients with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group.
Seibel NL; Li S; Breslow NE; Beckwith JB; Green DM; Haase GM; Ritchey ML; Thomas PR; Grundy PE; Finklestein JZ; Kim T; Shochat SJ; Kelalis PP; D'Angio GJ
J Clin Oncol; 2004 Feb; 22(3):468-73. PubMed ID: 14752069
[TBL] [Abstract][Full Text] [Related]
8. Results of two radiation therapy randomizations in the third National Wilms' Tumor Study.
Thomas PR; Tefft M; Compaan PJ; Norkool P; Breslow NE; D'Angio GJ
Cancer; 1991 Oct; 68(8):1703-7. PubMed ID: 1655223
[TBL] [Abstract][Full Text] [Related]
9. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
Malogolowkin M; Cotton CA; Green DM; Breslow NE; Perlman E; Miser J; Ritchey ML; Thomas PR; Grundy PE; D'Angio GJ; Beckwith JB; Shamberger RC; Haase GM; Donaldson M; Weetman R; Coppes MJ; Shearer P; Coccia P; Kletzel M; Macklis R; Tomlinson G; Huff V; Newbury R; Weeks D;
Pediatr Blood Cancer; 2008 Feb; 50(2):236-41. PubMed ID: 17539021
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
Spreafico F; Gandola L; D'Angelo P; Terenziani M; Collini P; Bianchi M; Provenzi M; Indolfi P; Pession A; Nantron M; Di Cataldo A; Marchianò A; Catania S; Fossati Bellani F; Piva L;
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):348-54. PubMed ID: 21075548
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms tumor.
Pachnis A; Pritchard J; Gaze M; Levitt G; Michalski A
Med Pediatr Oncol; 1998 Sep; 31(3):150-2. PubMed ID: 9722896
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative spillage of favorable histology wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group.
Kalapurakal JA; Li SM; Breslow NE; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; Thomas PR; Grundy P; Green DM; D'Angio GJ
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):201-6. PubMed ID: 19395185
[TBL] [Abstract][Full Text] [Related]
14. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
Tournade MF; Com-Nougué C; de Kraker J; Ludwig R; Rey A; Burgers JM; Sandstedt B; Godzinski J; Carli M; Potter R; Zucker JM;
J Clin Oncol; 2001 Jan; 19(2):488-500. PubMed ID: 11208843
[TBL] [Abstract][Full Text] [Related]
15. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.
Daw NC; Chi YY; Kim Y; Mullen EA; Kalapurakal JA; Tian J; Khanna G; Geller JI; Perlman EJ; Ehrlich PF; Warwick AB; Grundy PE; Fernandez CV; Dome JS;
Eur J Cancer; 2019 Sep; 118():58-66. PubMed ID: 31325873
[TBL] [Abstract][Full Text] [Related]
16. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Acha T; Godzinski J; Oldenburger F; Boccon-Gibod L; Leuschner I; Vujanic G; Sandstedt B; de Kraker J; van Tinteren H; Graf N;
Lancet; 2015 Sep; 386(9999):1156-64. PubMed ID: 26164096
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy for favorable histology Wilms tumor: prevention of flank recurrence did not improve survival on National Wilms Tumor Studies 3 and 4.
Breslow NE; Beckwith JB; Haase GM; Kalapurakal JA; Ritchey ML; Shamberger RC; Thomas PR; D'Angio GJ; Green DM
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):203-9. PubMed ID: 16542795
[TBL] [Abstract][Full Text] [Related]
18. Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Moksness J; Finklestein JZ; D'Angio GJ
J Clin Oncol; 1994 Oct; 12(10):2132-7. PubMed ID: 7931484
[TBL] [Abstract][Full Text] [Related]
19. Better survival after combined modality care for adults with Wilms' tumor. A report from the National Wilms' Tumor Study.
Arrigo S; Beckwith JB; Sharples K; D'Angio G; Haase G
Cancer; 1990 Sep; 66(5):827-30. PubMed ID: 2167146
[TBL] [Abstract][Full Text] [Related]
20. Abdominal irradiation in unilateral nephroblastoma and its impact on local control and survival.
Flentje M; Weirich A; Graf N; Pötter R; Zimmerman H; Ludwig R
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):163-9. PubMed ID: 9422573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
